ArticleACS synthetic biology2023
P1 Bacteriophage-Enabled Delivery of CRISPR-Cas9 Antimicrobial Activity Against
Article in ACS synthetic biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- CRISPR-Cas systems as next-generation antimicrobials: a systemic review of mechanisms, delivery strategies, and translational challenges.Frontiers in microbiology · 2026Pooled it
- Targeting Foodborne Pathogens with Bacteriophages: Mechanisms, Applications, and Resistance.Pathogens (Basel, Switzerland) · 2026Review
- Characterization of a novel phage-plasmid vB_EcoM_ED targeting multidrug-resistant Escherichia coli isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- DNA and RNA editing for the therapy of human diseases: current status, challenges, and future prospects.Molecular biomedicine · 2026Review
- Cross-order detection of bacteriophage transduction in microbial communities using RNA barcoding.Nature communications · 2026Article
- Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.Chemical science · 2026Review
- Nano-Enabled Delivery of Phage-Based Antibacterials Against ESKAPE Pathogens.Pharmaceutics · 2026Review
- Structure of defense against restriction proteins DarA and Hdf in phage P1 reveals a new molecular mechanism during phage assembly, infection and DNA ejection.PLoS pathogens · 2026Article
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- Synthetic and Functional Engineering of Bacteriophages: Approaches for Tailored Bactericidal, Diagnostic, and Delivery Platforms.Molecules (Basel, Switzerland) · 2025Review
- From resistance to remedy: the role of clustered regularly interspaced short palindromic repeats system in combating antimicrobial resistance-a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections.PHAGE (New Rochelle, N.Y.) · 2024Review
- Engineering probioticApplied and environmental microbiology · 2024Article
- Transcriptional profiling of zebrafish identifies host factors controlling susceptibility to Shigella flexneri.Disease models & mechanisms · 2024Article
- The untapped potential of phage model systems as therapeutic agents.Virus evolution · 2024Article
- Article
- An automated microscopy workflow to study Shigella-neutrophil interactions and antibiotic efficacy in vivo.Disease models & mechanisms · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
The discovery of clustered, regularly interspaced, short palindromic repeats (CRISPR) and the Cas9 RNA-guided nuclease provides unprecedented opportunities to selectively kill specific populations or species of bacteria. However, the use of CRISPR-Cas9 to clear bacterial infections
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.